Videos

Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.

Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.

Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.

An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.

Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.

An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.

Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.

Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.

Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.

Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.

A thought leader in hematology oncology highlights therapies currently in development for the management of CLL and provides closing remarks on unmet needs regarding patients who are double-refractory.

Jeff Sharman, MD, shares insight into best practices for monitoring and managing adverse effects of treatment in chronic lymphocytic leukemia including elevated liver function tests, diarrhea, and pneumocystis pneumonia.

An expert in the management of chronic lymphocytic leukemia discusses how patient- and disease-related factors influence treatment decisions after relapse.

A key opinion leader in hematology oncology provides an overview of treatment options for patients with newly diagnosed CLL and discusses factors to consider when monitoring patients for disease relapse.

Jeff Sharman, MD, reviews the initial presentation, clinical workup, and treatment of the case of a 73-year-old woman with chronic lymphocytic leukemia and shares insight into the patient’s prognosis and risk stratification.

Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.

Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.

Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.

An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.

Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.

Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.

Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.

Hossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.

An expert oncologist, Hossein Borghaei, DO considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed/refractory small-cell lung cancer.

A thought leader in lung cancer, Hossein Borghaei, DO, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.

Hossein Borghaei, DO, reviews the second-line treatment options in the setting of extensive-stage small cell lung cancer: topotecan or lurbinectedin.

Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.